wildpixel Agenus Inc. (NASDAQ:AGEN), a pioneer in immunological cancer treatments, has recently unveiled impressive results from the NEST-1 study. This investigator-sponsored trial ("IST") focused on evaluating the combination of botensilimab and balstilimab ((BOT/BAL)) in the neoadjuvant setting for colorectal cancer (CRC). The data from the NEST-1 study present BOT/BAL as a potential game-changer in CRC treatment. The combination's ability to induce significant tumor regression and eliminate ctDNA ope ...